Skip to main content
Lydia Visser
PhD

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

Antibodies against leucocyte common antigen (CD45). Applications in immunomodulation
Immune reactions in classical Hodgkin’s lymphoma
The immune reaction in classical Hodgkin’s lymphoma (HL) can be separated into an inflammatory response in the involved tissues and a generalized immune response in the patient. The local immune reaction in HL is by far the most prominent among all tumors, with the exception of so called T-cell-rich B-cell lymphoma, a subtype of large-cell B-cell lymphoma. The general immune response in patients with HL is best described as an acquired cellular immune deficiency, most likely a result of the presence of tumor, although some data in the...
S Poppema, M Potters, R Emmens, L Visser, A. van den Berg
High expression of the CC chemokine TARC in Reed-Sternberg cells: A possible explanation for the characteristic T-cell infiltrate in Hodgkin’s lymphoma
Published in: American Journal of Pathology
Hodgkin’s lymphoma is characterized by the combination of Reed-Sternberg (R-S) cells and a prominent inflammatory cell infiltrate. One of the intriguing questions regarding this disease is what is causing the influx of T lymphocytes into the involved tissues. We applied the serial analysis of gene expression (SAGE) technique on the Hodgkin’s lymphoma-derived cell line L428 and on an Epstein-Barr virus (EBV)-transformed lymphoblastoid B-cell line. A frequently expressed tag in L428 corresponded to the T-cell-directed CC chemokine TARC. Reverse transcription polymerase chain reaction analyses demonstrated expression of TARC in...
Mechanisms of induction of renal allograft tolerance in CD45RB-treated mice
Background. Rejection is the most significant problem in the field of transplantation. The current goal of transplant immunology is to develop better immunotherapeutic protocols that are aimed at specifically suppressing alloreactivity and preserving an otherwise intact immune system. We have previously shown that mice will accept renal allografts indefinitely with normal renal function after two injections of a monoclonal antibody to the CD45RB protein. Furthermore, this antibody will reverse acute rejection when therapy is delayed until day 4 and will still induce tolerance. The mechanisms of this therapeutic...
AI Lazarovits, L Visser, S Asfar, CE LeFeuvre-Haddad, T Zhong, DJ Kelvin, C Kong, MH Khandaker, B Singh, M White, AM Jevnikar, Z Zhang, S Poppema
Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy
CD45 is a family of transmembrane protein tyrosine phosphatases exclusively expressed by hematopoietic cells and critically involved in the regulation of T cell activation signals, We now demonstrate that three 100-mu g doses of antiCD45RB mAb MB23G2 can induce long-term engraftment of islets into major histcompatibility complex-disparate chemically diabetic mice, Long-term graft survivors (>120 days) were tolerant to new islet allografts from the original donor strain, MB23G2 induced a temporary decrease in number circulating leukocytes but had no effect on leukocyte number in other lymphoid compartments, Histologic examination...
GP Basadonna, L Auersvald, CQ Khuong, N Kashio, D Zekzer, M Minozzo, HY Qian, L Visser, A Diepstra, AI Lazarovits, S Poppema, TB Strom, DM Rothstein